Disturbance of the glutamatergic system in mice transgenic for the amyloid precursor protein

Alzheimer's Reports

Volumn 2, Issue 6, 1999, Pages 359-368

  Baekelandt, Veerle ^a   Moechars, Dieder ^a   Laenen, Isabelle ^a   Lorent, Kristin ^a   Van Leuven, Fred ^a  

^a Campus Gasthuisberg   (Belgium)

Author keywords

Alzheimer's disease; Excitotoxicity; Kainic acid NMDA; Receptor assay

Indexed keywords

EID: 22844454109     PISSN: 14616130     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (54)

1. Calligaro DO, O'Malley PJ and Monn JA (1993). beta-Amyloid (25-35). or substance P stimulates PI-TJMK-SOI binding to rat cortical membranes in the presence of glutamate and glycine. J Neurochem, 60,2297-2303.
2. Cohen SA and Müller WE (1992). Age-related alterations of NMDAreceptor properties in the mouse forebrain : partial restoration by chronic phosphatidylserine treatment. Brain Res 584,174-180.
3. Cowburn R, Hardy J, Roberts P and Briggs R (1988). Regional distribution of pre- and postsynaptic glutamatergic function in Alzheimer's disease. Brain Res 452, 403-407.
4. Cowburn RF, Messamore E, Li ML et a/(1994). beta-Amyloid related peptides exert differential effects on [3H]MK-801 binding to rat cortical membranes. NeuroReportS, 405-408.
5. Cowbum RF, Wiehager B, Trief E et al (1997). Effects of b-amyloid(25-35). peptides on radioligand binding to excitatory amino acid receptors and voltage-dependent calcium channels: evidence for a selective affinity for the glutamate and glycine recognition sites of the NMDA receptor. Neurochem Res 22,1437-1442.
6. Cullen WK, Wu J, Anwyl R and Rowan MJ (1996). beta-Amyloid produces a delayed NMDA receptor-dependent reduction in synaptic transmission in rat hippocampus. NeuroReportB, 87-92.
7. Feldmeyer D and Cull-Candy S (1996). Functional consequences of changes in NMDA receptor subunit expression during development. JNeurocytol25,857-867.
8. Fonnum F, MyhrerT, Paulsen RE ef a/(1995). Role of glutamate and glutamate receptors in memory function and Alzheimer's disease. Ann NYAcad Sci 757,475-486.
9. Foster AC, Mena EE, Monaghan DT and Cotman CW (1981). Synaptic localization of kainic acid binding sites. Nature 289, 73-75.
10. Furukawa K and Mattson MP (1998). Secreted amyloid precursor protein alpha selectively suppresses N-methyl-D-aspartate currents in hippocampal neurons: involvement of cyclic GMP. Neuroscience 83,429-438.
11. Gardner CR, Klein J and Grove J (1981 ). Endogenous GABA determines the characteristics of [3H]GABA-binding . Eur J P/7am?aco/75,83-92.
12. Gavrieli Y, Sherman Y and Ben-Sasson SA (1992). Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J Cell B/o/119,493-501.
13. Greenamyre JT and Maragos WF (1993). Neurotransmitter receptors in Alzheimer disease. Cerebrovasc Brain Metab Rev 5,61-94.
14. Jimenez-Jimenez FJ, Molina JA, Gomez P étal (1998). Neurotransmitter amino acids in cerebrospinal fluid of patients with Alzheimer's disease. J Neural Transm 105,269-277.
15. Johnson JW and Ascher P (1987). Glycine potentiates the NMDA response in cultured mouse brain neurons. Nature 325, 529531.
16. Jones RW, Wesnes KAand Kirby J (1991). Effects of NMDA modulation in scopolamine dementia. Ann NYAcad Sci 640, 241244.
17. Koh JY, Yang LL and Cotman CW (1990). Beta-amyloid protein increases the vulnerability of cultured cortical neurons to excitotoxic damage. Brain Res 533,315-320.
18. Kürschner VC, Petruzzi RL, Golden GT et a/(1998). Kainate and AMPA receptor binding in seizure-prone and seizure-resistant inbred mouse strains. Brain Res 780,1-8.
19. Lerea LS (1997). Glutamate receptors and gene induction: signalling from receptor to nucleus. Cell Signal 9,219-226.
20. Li S, Mallory M, Alford M et al (1997). Glutamate transport er alterations in Alzheimer disease are possibly associated with abnormal APP expression. J Neuropathol Exp Neurol 56,901-911.
21. London ED and Coyle JT (1979). Specific binding of pH]kainic acid to receptor sites in rat brain. Mol Pharmacol 15,492-505.
22. Maragos WF, Greenamyre JT, Penney JB and Young AB (1987). Glutamate dysfunction in Alzheimer's disease : an hypothesis. Trends Neurosci 10,65-68.
23. Masliah E (1998). Mechanisms of synaptic pathology in Alzheimer's disease. J Neural Transm Supp/53,147-158.
24. Masliah E, Alford M, DeTeresa R et al (1996). Deficient glutamate transport is associated with neurodegeneration in Alzheimer's disease. Ann Neurol40,759-766.
25. Mattson MP, Cheng B, Culwell AR ef a/ (1993). Evidence for excitoprotective and intraneuronal calcium-regulating roles for secreted forms of the beta-amyloid precursor protein. Neuron 10,243-254.
26. Mattson MP, Cheng B, Davis D ef a/(1992). beta-Amyloid peptides destabilize calcium homeostasis and render human cortical neurons vulnerable to excitotoxicity. J Neurose/12,376-389.
27. Meoni P, Mugnaini M, Bunnemann BH et al (1998). [3H]MK-801 binding and the mRNA for the NMDAR1 subunit of the NMDA receptor are differentially distributed in human and rat forebrain. Mol Brain Res 54,13-23.
28. Miller LP, Johnson AE, Gelhard RE and Insel TR (1990). The ontogeny of excitatory amino acid receptors in the rat forebrain-II Kainic acid receptors. Neuroscience 35,45-51.
29. Moechars D, Lorent K, De Strooper B étal. (1996). Expression in brain of amyloid precursor protein mutated in the alpha-secretase site causes disturbed behavior, neuronal degeneration and premature death in transgenic mice. EMBOJIS, 1265-1274.
30. Moechars D, Dewachterl, Lorent Kef aJ. (1999a). Early phenotypic changes in transgenic mice that overexpress different mutants of amyloid precursor protein in brain. JS/o/ Chem 274, 6483-6492.
31. Moechars D, Lorent K and Van Leuven F (1999b). Premature death in transgenic mice that overexpress a mutant Amyloid precursor protein is preceded by severe neurodegeneration and apoptosis/Veurosc/ence91,819-830.
32. Monaghan DT and Cotman CW (1982). The distribution of pH]kainic acid binding sites in rat CNS as determined by autoradiography. Brain Res 252,91-100.
33. Morgan Jl, Cohen DR, Hempstead JL and Curran T (1987). Mapping patterns of c-fos expression in the central nervous system after seizure. Science 237,192-197.
34. Morgan Jl and Curran T (1991 ). Stimulus-transcription coupling in the nervous system: involvement of the inducible protooncogenes fos and jun. Ann Rev Neurose/14,421-451.
35. Morrison RS, Wenzel HJ, Kinoshita Y et al. (1996). Loss of p53 Tumor suppresser gene protects neurons from kainate-induced cell death. J Neurosci 16,1337-1345.
36. Nalbantoglu J, Tirado-Santiago G, Lahsaini A er aj. (1997). Impaired learning and LTP in mice expressing the carboxy terminus of the Alzheimer amyloid precursor protein. Nature 387,500-505
37. Ozawa S, Kamiya H and Tsuzuki K (1998). Glutamate receptors in the mammalian CNS. ProgNeurobiol54,581-618.
38. Palmer AM and Bums MA (1994). Preservation of redox, polyamine, and glycine modulatory domains of the N-methyl-D-aspartate receptor in Alzheimer's disease. JNeurochem 62,187-196.
39. Porter RH, Roberts PJ and Briggs RS (1993). NMDA receptor status in elderly normal individuals and those with Alzheimer's disease Ann NYAcad Sci 695, 50-53.
40. Portera-Cailliau C, Price DL and Martin LJ (1997). Non-NMDA and NMDA receptor-mediated excitotoxic neuronal deaths in adult brain are morphologically distinct: further evidence for an apoptosis-necrosis continuum. J Comp Neurol378,88-104.
41. Procter AW, Wong EH, Stratmann GC ef a/(1989). Reduced glycine stimulation of PHJMK-801 binding in Alzheimer's disease. JNeurochem 53,698-704.
42. Ransom RW and Stec NL (1988). Cooperative modulation of PH]MK801 binding to the N-methyl-D-aspartate receptor-ion channel complex by L-glutamate, glycine, and polyamines. JNeurochem 51,830-836.
43. Reynolds I J, Murphy SN and Miller RJ (1987). 3H -labeled MK-801 binding to the excitatory amino acid receptor complex from rat brain is enhanced by glycine. Proc Natl Acad Sci USA 84, 7744.7748.
44. Rothstein JD, Jin L, Dykes-Hoberg M and Kuncl RW (1993). Chronic inhibition of glutamate uptake produces a model of slow neurotoxicity. Proc Natl Acad Sci USA 90, 6591-6595.
45. Sakurai SY, Cha JH, Penney JB and Young AB (1991). Regional distribution and properties of [3H]MK-801 binding sites determined by quantitative autoradiography in rat brain. Neuroscience 40,533-543.
46. Sandhu FA, Porter RH, Eller RV et al (1993). NMDA and AMPA receptors in transgenic mice expressing human beta-amyloid protein. JNeurochem 61,2286-2289.
47. Schwartz BL, Hashtroudi S, Herting RL et al (1996). d-Cycloserine enhances implicit memory in Alzheimer patients. Neurology 46,420-424.
48. Schwob JE, Fuller T, Price JL and Olney JW (1980). Widespread patterns of neuronal damage following systemic or intracerebral injections of kainic acid: a histological study. Neuroscience 5, 991-1014.
49. Selkoe DJ (1994). Cell biology of the amyloid beta-protein precur-sor and the mechanism of Alzheimer's disease. Ann Rev Cell Biol10,373-403.
50. Thorns V, Mallory M, Hansen L and Masliah E (1997). Alterations in glutamate receptor 2/3 subunits and amyloid precursor protein expression during the course of Alzheimer's disease and Lewy body variant. Acta Neuropathol (Berl) 94,539-548.
51. Wong EH, Kemp JA, Priestley T ef a/ (1986). The anticonvulsant MK-801 is a potent N-methyl-D-aspartate antagonist. Proc Natl Acad Sci USA 83,7104-7108.
52. Wu J, Anwyl R and Rowan MJ (1995). beta-Amyloid selectively augments NMDA receptor-mediated synaptic transmission in rat hippocampus. NeuroReportG, 2409-2413.
53. Yamakura T, Mori H, Masaki H et al (1993). Different sensitivities of NMDA receptor channel subtypes to non-competitive antagonists. NeuroReport 4, 687-690.
54. Yankner BA (1996). Mechanisms of neuronal degeneration in Alzheimer's disease. Neuron 16, 921-932.